ABL1 and Parkinson disease: Recent reports show that c-Abl inhibitors are being used in clinical trials for different neurodegenerative pathologies, including Parkinson’s disease (Abushouk et al., 2018; Pagan et al., 2019) and other Dementias (Pagan et al., 2016), Huntington’s disease (Clinical trial gov identifier NCT03764215) and Alzheimer’s disease (NCT02947893) (Turner et al., 2020).